Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C

Meta-analysis of individual patient data from six clinical trials

Alessandra Mangia, Gioacchino Leandro, Beat Helbling, Eberhard L. Renner, Marco Tabone, Laura Sidoli, Simona Caronia, Graham R. Foster, Stephan Zeuzem, Thomas Berg, Vito Di Marco, Nicolina Cino, Angelo Andriulli

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5% (95% CI 34.1-42.8) after INF and AMA, and 29.5% (95% CI 25.5-33.6) after INF alone (P=0.003). Sustained response occurred in 111 (23.1%; 95% CI 19.3-20.2) and 85 patients (17.3%; 95% CI 14.0-20.7), respectively (P=0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P=0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.

Original languageEnglish
Pages (from-to)478-483
Number of pages6
JournalJournal of Hepatology
Volume40
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Amantadine
Chronic Hepatitis C
Interferons
Meta-Analysis
Clinical Trials
Ribavirin
Viremia
Therapeutics
Genotype

Keywords

  • Amantadine
  • Chronic hepatitis C
  • Interferon
  • Meta-analysis
  • Randomized clinical trials
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C : Meta-analysis of individual patient data from six clinical trials. / Mangia, Alessandra; Leandro, Gioacchino; Helbling, Beat; Renner, Eberhard L.; Tabone, Marco; Sidoli, Laura; Caronia, Simona; Foster, Graham R.; Zeuzem, Stephan; Berg, Thomas; Di Marco, Vito; Cino, Nicolina; Andriulli, Angelo.

In: Journal of Hepatology, Vol. 40, No. 3, 03.2004, p. 478-483.

Research output: Contribution to journalArticle

Mangia, Alessandra ; Leandro, Gioacchino ; Helbling, Beat ; Renner, Eberhard L. ; Tabone, Marco ; Sidoli, Laura ; Caronia, Simona ; Foster, Graham R. ; Zeuzem, Stephan ; Berg, Thomas ; Di Marco, Vito ; Cino, Nicolina ; Andriulli, Angelo. / Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C : Meta-analysis of individual patient data from six clinical trials. In: Journal of Hepatology. 2004 ; Vol. 40, No. 3. pp. 478-483.
@article{bc0adc6cba4c4f30880aeb77522c440f,
title = "Combination therapy with amantadine and interferon in na{\"i}ve patients with chronic hepatitis C: Meta-analysis of individual patient data from six clinical trials",
abstract = "Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5{\%} (95{\%} CI 34.1-42.8) after INF and AMA, and 29.5{\%} (95{\%} CI 25.5-33.6) after INF alone (P=0.003). Sustained response occurred in 111 (23.1{\%}; 95{\%} CI 19.3-20.2) and 85 patients (17.3{\%}; 95{\%} CI 14.0-20.7), respectively (P=0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P=0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.",
keywords = "Amantadine, Chronic hepatitis C, Interferon, Meta-analysis, Randomized clinical trials, Therapy",
author = "Alessandra Mangia and Gioacchino Leandro and Beat Helbling and Renner, {Eberhard L.} and Marco Tabone and Laura Sidoli and Simona Caronia and Foster, {Graham R.} and Stephan Zeuzem and Thomas Berg and {Di Marco}, Vito and Nicolina Cino and Angelo Andriulli",
year = "2004",
month = "3",
doi = "10.1016/j.jhep.2003.11.002",
language = "English",
volume = "40",
pages = "478--483",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C

T2 - Meta-analysis of individual patient data from six clinical trials

AU - Mangia, Alessandra

AU - Leandro, Gioacchino

AU - Helbling, Beat

AU - Renner, Eberhard L.

AU - Tabone, Marco

AU - Sidoli, Laura

AU - Caronia, Simona

AU - Foster, Graham R.

AU - Zeuzem, Stephan

AU - Berg, Thomas

AU - Di Marco, Vito

AU - Cino, Nicolina

AU - Andriulli, Angelo

PY - 2004/3

Y1 - 2004/3

N2 - Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5% (95% CI 34.1-42.8) after INF and AMA, and 29.5% (95% CI 25.5-33.6) after INF alone (P=0.003). Sustained response occurred in 111 (23.1%; 95% CI 19.3-20.2) and 85 patients (17.3%; 95% CI 14.0-20.7), respectively (P=0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P=0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.

AB - Background/Aims: In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods: Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre-treatment interaction fitted as random variables. Results: At the end of therapy, virological responses were 38.5% (95% CI 34.1-42.8) after INF and AMA, and 29.5% (95% CI 25.5-33.6) after INF alone (P=0.003). Sustained response occurred in 111 (23.1%; 95% CI 19.3-20.2) and 85 patients (17.3%; 95% CI 14.0-20.7), respectively (P=0.03). Even accounting for the centre effect, therapy with AMA and INF was more effective than IFN alone (P=0.029). When genotypes and viraemia levels were combined, the response rate after combination therapy doubled that observed with IFN alone in all subgroups, except those with low viraemia and genotypes 2 or 3. Conclusions: In chronic hepatitis C, therapy with AMA and INF is effective and may be an alternative to INF and ribavirin in patients who cannot tolerate ribavirin.

KW - Amantadine

KW - Chronic hepatitis C

KW - Interferon

KW - Meta-analysis

KW - Randomized clinical trials

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=10744224044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744224044&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2003.11.002

DO - 10.1016/j.jhep.2003.11.002

M3 - Article

VL - 40

SP - 478

EP - 483

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -